Sex-specific cut-off values for soluble suppression of tumorigenicity 2 (ST2) biomarker increase its cardiovascular prognostic value in the community

References

• AbouEzzeddine, O.F., et al., 2016. Biomarker-based risk prediction in the community. European journal of heart failure, 18 (11), 1342–1350.
   PubMed Web of Science ®Google Scholar
• AbouEzzeddine, O.F., et al., 2017. Suppression of tumorigenicity 2 in heart failure with preserved ejection fraction. Journal of the American heart association, 6 (2), e004382.
   PubMed Web of Science ®Google Scholar
• Agarwal, S.K., et al., 2012. Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation heart failure, 5 (4), 422–429.
   PubMed Web of Science ®Google Scholar
• Anand, I.S., et al., 2014. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Circulation: heart failure, 7 (3), 418–426.
   PubMed Web of Science ®Google Scholar
• Beale, A.L., et al., 2018. Sex differences in cardiovascular pathophysiology: why women are overrepresented in heart failure with preserved ejection fraction. Circulation, 138 (2), 198–205.
   PubMed Web of Science ®Google Scholar
• Borlaug, B.A., et al., 2010. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circulation: heart failure, 3 (5), 588–595.
   PubMed Web of Science ®Google Scholar
• Broch, K., et al., 2012. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. European journal of heart failure, 14 (3), 268–277.
   PubMed Web of Science ®Google Scholar
• Chen, W.Y., et al., 2015. Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33. Proceedings of the national academy of sciences of the united states of America, 112 (23), 7249–7254.
   PubMed Web of Science ®Google Scholar
• Cho, L., et al., 2020. Summary of updated recommendations for primary prevention of cardiovascular disease in women: JACC state-of-the-art review. Journal of the American college of cardiology, 75 (20), 2602–2618.
   PubMed Web of Science ®Google Scholar
• Coglianese, E.E., et al., 2012. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clinical chemistry, 58 (12), 1673–1681.
   PubMed Web of Science ®Google Scholar
• Contal, C. and O’Quigley, J., 1999. An application of changepoint methods in studying the effect of age on survival in breast cancer. Computational statistics & data analysis, 30 (3), 253–270.
   Web of Science ®Google Scholar
• Dallmeier, D., et al., 2015. Sex-specific associations of established and emerging cardiac biomarkers with all-cause mortality in older adults: the ActiFE study. Clinical chemistry, 61 (2), 389–399.
   PubMed Web of Science ®Google Scholar
• Daniels, L.B. and Maisel, A.S., 2015. Cardiovascular biomarkers and sex: the case for women. Nature reviews cardiology, 12 (10), 588–596.
   PubMed Web of Science ®Google Scholar
• Dieplinger, B., et al., 2009. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma–the Presage ST2 assay. Clinica chimica acta, 409 (1–2), 33–40.
   PubMed Web of Science ®Google Scholar
• Gerdts, E. and Regitz-Zagrosek, V., 2019. Sex differences in cardiometabolic disorders. Nature medicine, 25 (11), 1657–1666.
   PubMed Web of Science ®Google Scholar
• Goff, D.C., Jr., et al., 2014. ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American college of cardiology, 63 (25), 2935–2959.
   PubMed Web of Science ®Google Scholar
• Hughes, M.F., et al., 2014. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality. Heart (British cardiac society), 100 (21), 1715–1721.
   PubMed Web of Science ®Google Scholar
• Jacobsen, S.J., et al., 2004. Participation bias in a population-based echocardiography study. Annals of epidemiology, 14 (8), 579–584.
   PubMed Web of Science ®Google Scholar
• Jaffe, A.S. and Apple, F.S., 2014. High-sensitivity cardiac troponin assays: isn't it time for equality? Clinical chemistry, 60 (1), 7–9.
   PubMed Web of Science ®Google Scholar
• Kakkar, R. and Lee, R.T., 2008. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nature reviews drug discovery, 7 (10), 827–840.
   PubMed Web of Science ®Google Scholar
• Levey, A.S., 1999. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of internal medicine, 130 (6), 461–470.
   PubMed Web of Science ®Google Scholar
• Lotierzo, M., et al., 2020. sST2 as a value-added biomarker in heart failure. Clinica chimica acta; international journal of clinical chemistry, 501, 120–130.
   PubMed Web of Science ®Google Scholar
• Manzano-Fernández, S., et al., 2013. Comparison of risk prediction with the CKD-EPI and MDRD equations in acute decompensated heart failure. Journal of cardiac failure, 19 (8), 583–591.
   PubMed Web of Science ®Google Scholar
• McKie, P.M., et al., 2010. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. Journal of the American college of cardiology, 55 (19), 2140–2147.
   PubMed Web of Science ®Google Scholar
• McKie, P.M., et al., 2013. Defining high-sensitivity cardiac troponin concentrations in the community. Clinical chemistry, 59 (7), 1099–1107.
   PubMed Web of Science ®Google Scholar
• Melton, L.J., 3rd. 1996. History of the Rochester epidemiology project. Mayo clinic proceedings, 71 (3), 266–274.
   PubMed Web of Science ®Google Scholar
• Nagy, A.I., et al., 2018. Left atrial rather than left ventricular impaired mechanics are associated with the pro-fibrotic ST2 marker and outcomes in heart failure with preserved ejection fraction. Journal of internal medicine, 283 (4), 380–391.
   PubMed Web of Science ®Google Scholar
• Pacho, C., et al., 2018. Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients. BMC geriatrics, 18 (1), 109.
   PubMedGoogle Scholar
• Redfield, M.M., et al., 2002. Plasma brain natriuretic peptide concentration: impact of age and gender. Journal of the American college of cardiology, 40 (5), 976–982.
   PubMed Web of Science ®Google Scholar
• Redfield, M.M., et al., 2003. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA, 289 (2), 194–202.
   PubMed Web of Science ®Google Scholar
• Shufelt, C.L., et al., 2018. Sex-specific physiology and cardiovascular disease. Advances in experimental medicine and biology, 1065, 433–454.
   PubMed Web of Science ®Google Scholar
• Vasiljevic, Z., et al., 2018. Coronary microcirculation in heart failure with preserved systolic function. Current pharmaceutical design, 24 (25), 2960–2966.
   PubMed Web of Science ®Google Scholar
• Weinberg, E.O., et al., 2002. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation, 106 (23), 2961–2966.
   PubMed Web of Science ®Google Scholar
• Yancy, C.W., et al., 2013. ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation, 128 (16), 1810–1852.
   PubMed Web of Science ®Google Scholar
• Zile, M.R., et al., 2016. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study. Circulation heart failure, 9 (1), e002551.
   PubMed Web of Science ®Google Scholar